Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Acquisition (Details)

Acquisition (Details) (USD $)	0 Months Ended	12 Months Ended	0 Months Ended
Acquisition (Details) (USD $)	Oct. 31, 2014	Dec. 31, 2014	Aug. 13, 2014	Dec. 31, 2013	Aug. 31, 2013
Business Acquisition [Line Items]
Cash paid to acquire business		$ 13,359,000
Finite-lived intangible assets, gross		47,468,000
Contingent consideration, liability		26,542,000			500,000
Common stock, par value (usd per share)		$ 0.01		$ 0.01
Goodwill		15,545,000us-gaap_Goodwill		0us-gaap_Goodwill
FDIC indemnification asset, acquisitions	2,500,000
Interpace Diagnostics, LLC
Business Acquisition [Line Items]
Assets acquired, samples			5,000
Cash paid to acquire business			8,000,000
Other Commitment			500,000
Finite-lived intangible assets, gross			13,000,000
Finite-lived intangible asset, useful life			7 years 10 months 24 days
Contingent consideration, liability			4,476,000
RedPath Integrated Pathology, Inc
Business Acquisition [Line Items]
Cash paid to acquire business	13,400,000
Contingent consideration, liability	23,886,000
Working capital adjustment	1,600,000	1,820,000
Contingent cash payments on annual net sales	5,000,000
Goodwill	15,545,000
Maximum \| RedPath Integrated Pathology, Inc
Business Acquisition [Line Items]
Maximum quarterly principal payment	250,000
Diagnostic Test - Pancreas \| Interpace Diagnostics, LLC
Business Acquisition [Line Items]
Royalty Percentage			5.00%
Royalty Percentage Period			10 years
Diagnostic Test - Thyroid \| Interpace Diagnostics, LLC
Business Acquisition [Line Items]
Royalty Percentage			3.50%
Diagnostic Test- Other Thyroid \| Interpace Diagnostics, LLC
Business Acquisition [Line Items]
Royalty Percentage			1.50%
Royalty Percentage Period			10 years
Barrett's Esophagus \| RedPath Integrated Pathology, Inc
Business Acquisition [Line Items]
Annual net sales threshold	14,000,000
Interpace and RedPath \| RedPath Integrated Pathology, Inc
Business Acquisition [Line Items]
Annual net sales threshold	37,000,000
Notes Payable, Other Payables
Business Acquisition [Line Items]
Long-term debt		7,500,000
Notes Payable, Other Payables \| RedPath Integrated Pathology, Inc
Business Acquisition [Line Items]
Number of equal consecutive quarterly installments	8
Stated interest rate	5.00%
Long-term debt		7,300,000
Debt discount rate		13.50%
Equity interests issued	500,000
Common stock, par value (usd per share)	$ 0.01
Face amount	11,000,000
Loans \| RedPath Integrated Pathology, Inc
Business Acquisition [Line Items]
Stated interest rate	1.00%
Long-term debt		19,700,000
Face amount	20,000,000
Proceeds from issuance of debt	19,600,000
Margin on interest rate	12.50%
Interest rate, increase in case of default	3.00%
Loan Processing Fee	300,000
Exit Fee	800,000
Prepayment premium, base amount	80,000,000
PathFinderTG \| RedPath Integrated Pathology, Inc
Business Acquisition [Line Items]
Royalty Percentage			10.00%
Annual net sales threshold	30,000,000
Barrett's Esophagus \| RedPath Integrated Pathology, Inc
Business Acquisition [Line Items]
Royalty Percentage			20.00%
Annual net sales threshold	30,000,000
PathFinderTG-Pancreas \| RedPath Integrated Pathology, Inc
Business Acquisition [Line Items]
Royalty Percentage			6.50%
Annual net sales threshold	12,000,000
Molecular Diagnostics \| Maximum \| RedPath Integrated Pathology, Inc
Business Acquisition [Line Items]
Quarterly revenue based payments, percent of net sales	1.25
RedPath
Business Acquisition [Line Items]
Finite-lived intangible assets, gross			34,500,000
Finite-lived intangible asset, useful life			8 years 0 months 22 days
Goodwill		15,545,000
On or After October 31, 2015 \| Loans \| RedPath Integrated Pathology, Inc
Business Acquisition [Line Items]
Prepayment fee percent	6.00%
Between October 31, 2016 and October 31, 2017 \| Loans \| RedPath Integrated Pathology, Inc
Business Acquisition [Line Items]
Prepayment fee percent	5.00%
Prepayment premium	1.25%
Between October 31, 2007 and October 31, 2008 \| Loans \| RedPath Integrated Pathology, Inc
Business Acquisition [Line Items]
Prepayment fee percent	2.00%
Reported Value Measurement [Member]
Business Acquisition [Line Items]
Contingent consideration, liability		26,542,000
Reported Value Measurement [Member] \| RedPath
Business Acquisition [Line Items]
Contingent consideration, liability		$ 22,066,000